



(12) **United States Patent**
Ulrich et al.

(10) **Patent No.:** **US 8,710,185 B2**
(45) **Date of Patent:** **Apr. 29, 2014**

(54) **BACTERIAL SUPERANTIGEN VACCINES**

(75) Inventors: **Robert G. Ulrich**, Frederick, MD (US);
Mark A. Olson, Gaithersburg, MD (US);
Sina Bavari, Dillsburg, PA (US)

(73) Assignee: **The United States of America as
represented by the Secretary of the
Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/304,835**

(22) Filed: **Nov. 28, 2011**

(65) **Prior Publication Data**

US 2012/0148601 A1 Jun. 14, 2012

Related U.S. Application Data

(62) Division of application No. 12/151,497, filed on May
7, 2008, now Pat. No. 8,067,202, which is a division of
application No. 10/767,687, filed on Jan. 29, 2004,
now Pat. No. 7,378,257, which is a division of
application No. 08/882,431, filed on Jun. 25, 1997,
now Pat. No. 6,713,284.

(51) **Int. Cl.**
C07K 14/31 (2006.01)

(52) **U.S. Cl.**
USPC **530/350**

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,399,332 B1	6/2002	Ulrich et al.	435/69.3
6,713,284 B2	3/2004	Ulrich et al.	435/69.3
7,087,235 B2	8/2006	Ulrich et al.	424/236.1
7,378,257 B2	5/2008	Ulrich	
8,067,202 B2	11/2011	Ulrich	

OTHER PUBLICATIONS

Jones et al., Journal of Bacteriology, 166:29-33, 1986.*
Hayball et al., "Identification of two binding sites in *Staphylococcal*
enterotoxin B that confer specificity for TCR Vbeta gene products",
International Immunology, vol. 6, No. 2, pp. 199-211 (1994).
Bavari et al., "Engineered Bacterial Superantigen Vaccines", Vac-
cines 96, pp. 135-141 (1996).
Bavari et al., "Superantigen Vaccines: A Comparative Study of
Genetically Attenuated Receptor-Binding Mutants of *Staphylococcal*
enterotoxin A", J. Infectious Diseases, 1996, 174:338-345.

Hurley et al., "Identification of Class II Major Histocompatibility
Complex and T Cell Receptor Binding Sites in the Superantigen
Toxic Shock Syndrome Toxin 1", J. Exp. Med., vol. 181, 2229-2235,
Jun. 1995.

Stiles, et al., "Toxicity of *Staphylococcal enterotoxins* Potentiated by
Lipopolysaccharide: Major Histocompatibility Complex Class II
Molecule Dependency and Cytokine Release", Infection and Immu-
nity, vol. 61, No. 12, pp. 5333-5338, Dec. 1993.

Dannecker et al. (1994) Activation of human T cells by the
superantigen *Staphylococcus enterotoxin B*: Analysis on a cellular
level. *Immunobiology* 190: 116-126.

Gonzalo et al. (1992) Expansion and clonal deletion of peripheral T
cells induced by bacterial superantigen is independent of the
interleukin-2 pathway. *Eur. J. Immunol.* 22:1007-1011.

Bavari et al. (1995) Genetically attenuated bacterial superantigen
vaccines. *J. Cellular Biochemistry* Suppl. 21A. abstract C2-204 p. 88.

Bavari et al. (1995) *Staphylococcal enterotoxin A* and toxin shock
syndrome toxin compete with CD4 for human major histocompat-
ibility complex class II binding. *Infection and Immunity* 63:423-429.

Mahana et al. (1995) A natural mutation of the amino acid residue at
position 60 destroys *Staphylococcal enterotoxin A* marine T-cell
mitogenicity. *Infection and Immunity* 63:2826-2832.

Woody et al. (1998) Differential Immune responses to *Staphylococ-
cal enterotoxin B* mutations in a hydrophobic loop dominating the
interface with major histocompatibility complex class II receptors. *J.
Infectious Diseases* 177: 1013-1022.

Bavari, S. et al. (1996) Superantigen vaccines: A comparative study
of genetically attenuated receptor-binding mutants of *Staphylococcal*
enterotoxin A. *J. Inf. Dis.* 174:338-345.

Ulrich, R. G. et al. (1995) *Staphylococcal enterotoxins A* and *B* share
a common structural motif for binding class II major histocompat-
ibility complex molecules. *Nature Structural Biology* 2:554-560.
Stiles, B. G. et al. (1993) Toxicity of *Staphylococcal enterotoxins*
potentiated by lipopolysaccharide: major histocompatibility com-
plex class II molecule dependency and cytokine release. *Infect.
Immun.* 61:5333-5338.

Hurley, J. M. et al. (1995) Identification of class II major
histocompatibility complex and T cell receptor binding sites in the
superantigen toxin shock syndrome toxin 1. *J. Exp. Med.* 181:2229-
2234.

Ulrich, R. G. et al. (1995) Bacterial superantigens in human disease:
structure, function and diversity. *Trends in Microbiology* 3: 463-468.

* cited by examiner

Primary Examiner — Marianne P Allen

(74) *Attorney, Agent, or Firm* — Elizabeth Arwine

(57) **ABSTRACT**

The present invention relates to genetically attenuated super-
antigen toxin vaccines altered such that superantigen
attributes are absent, however the superantigen is effectively
recognized and an appropriate immune response is produced.
The attenuated superantigen toxins are shown to protect ani-
mals against challenge with wild type toxin. Methods of
producing and using the altered superantigen toxins are
described.

4 Claims, 8 Drawing Sheets